The present invention relates to a form 1 and form 2 polymorph of (-)-trans -3 -(5,6- dihydro-4H-pyrrolo [3,2,1-ij] quinolin-1-yl)-4-(1H-indol-3-yl) pyrrolidine-2,5-dione. The present invention also relates to (-)-trans-3-(5,6-dihydro-4H-pyrrolo [3,2,1-ij] quinolin-1-yl)-4- (1H-indol-3-yl) pyrrolidine-2, 5-dione compounds having a chiral purity greater than 99%, and methods of preparation of these compounds. The present invention also relates to pharmaceutical compositions comprising these (-)-trans-3-(5,6-dihydro-4H-pyrrolo [3,2,1-ij] quinolin-l-yl)-4-(lH-indol-3-yl) pyrrolidine-2, 5-dione compounds. The present invention provides methods of treating a cell proliferative disorder, such as a cancer, by administering to a subject in need thereof a therapeutically effective amount of a composition comprising (-)-trans- 3-(5,6-dihydro-4H-pyrrolo [3,2,1-ij] quinolin-l-yl)-4-(lH-indol-3-yl) pyrrolidine-2, 5-dione having a chiral purity greater than 99% or a form 1 and form 2 polymorph of (-)-trans -3 -(5,6- dihydro-4H-pyrrolo [3,2,1-ij] quinolin-1-yl)-4-(1H-indol-3-yl) pyrrolidine-2,5-dione.La présente invention concerne les formes polymorphes 1 et 2 de la (-)-trans-3-(5,6-dihydro-4H-pyrrolo[3,2,1-ij]quinolin-1-yl)-4- (1H-indol-3-yl)pyrrolidine-2,5-dione. La présente invention concerne également des composés de (-)-trans-3-(5,6-dihydro-4H-pyrrolo[3,2,1-ij] quinolin-1-yl)-4-(1H-indol-3-yl)pyrrolidine-2,5-dione dont la pureté chirale est supérieure à 99 %, ainsi que des procédés de préparation de ces composés. La présente invention concerne également des compositions pharmaceutiques contenant ces composés de (-)-trans-3-(5,6-dihydro-4H- pyrrolo[3,2,1-ij]quinolin-l-yl)-4-(lH-indol-3-yl)pyrrolidine-2,5-dione. La présente invention concerne des méthodes de traitement dune affection caractérisée par une prolifération cellulaire, comme le cancer, grâce à ladministration à un sujet en ayant besoin dune quantité thérapeutiquement efficace dune composition contenant de la (-)-tran
